INCADRONATE (cas 138330-18-4) inhibits osteoporosis in ovariectomized rats

Add time:08/21/2019    Source:sciencedirect.com

INCADRONATE (cas 138330-18-4) is a highly effective inhibitor of stimulated bone resorption as demonstrated in a hypercalcemia model in rats, bone metastasis models in mice and rats, and an osteoporosis model in dogs. In this study, the effect of incadronate on osteoporosis in ovariectomized rats was examined. Incadronate dose-dependently inhibited decreases in second lumbar vertebrae bone mineral density (BMD) following oral administration for 4 or 12 weeks. Significant inhibition was observed at doses of more than 0.3 mg/kg. Incadronate dose-dependently inhibited the loss of distal femur metaphyseal compressive strength following 12 weeks of oral administration, and this was significant at a 3 mg/kg daily dose. Incadronate also dose-dependently inhibited the increases in urinary deoxypyridinoline levels after 4-or 12-week oral administrations. While incadronate had no effect on serum osteocalcin levels after 4 weeks of oral administration, it did dose-dependently reduce levels after 12 weeks of oral administration. These results suggested that incadronate may be a useful drug for osteoporosis due to stimulated bone resorption.

We also recommend Trading Suppliers and Manufacturers of INCADRONATE (cas 138330-18-4). Pls Click Website Link as below: cas 138330-18-4 suppliers

Prev:INCADRONATE (cas 138330-18-4) inhibits aminopeptidase N expression in prostatic PC-3 cells
Next:From Lab to ClinicLack of Prophylactic Effect of INCADRONATE (cas 138330-18-4) on Skeletal Lesions Associated with Implants of Prostate Cancer☆)